| 引用本文:王志飞 谢雁鸣.中药上市后再评价发展概述[J].世界中医药,2014,9(09):. |
|
| 中药上市后再评价发展概述 |
| Summary on Evaluation of Post-marketing Chinese Medicines |
| 投稿时间：2014-08-06 |
| DOI：10.3969/j.issn.1673-7202.2014.09.001 |
| 中文关键词: 中药上市后再评价 证据体 综述 |
| English Keywords:Evaluation of post-marketing Chinese medicines Body of evidence Literature review |
| 基金项目:“重大新药创制”科技重大专项“中药上市后再评价关键技术研究”（编号：2009ZX09502-030）；中国中医科学院科技创新团队建设项目(编号：PY1303) |
|
| 摘要点击次数: 1162 |
| 全文下载次数: 1591 |
| 中文摘要: |
| 中药上市后再评价经历10余年发展，取得较大成就，影响日益深刻。本文从中药上市后再评价的发展历程、法规现状和研究现状3个方面概述了其发展状况，评述了其发展热点，分析了其发展的趋势，为了解中药上市后再评价的发展提供参考。 |
| English Summary: |
| After 10 years of development, the research of evaluation of post-marketing Chinese medicines has made great achievements. This article makes a review on the history, legislation, research status quo in the area, makes a commentary of the hot spots of development, analyzes development trend so as to provide a reference for further developing evaluation of post-marketing Chinese medicines. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
